Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate

[Guest guest]

http://www.mdlinx.com/infectious-disease/newsl-article.cfm/3750503/ZZ68065536792\

5639220014/?news_id=497 & newsdt=091311 & subspec_id=130

Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative

patient with rheumatoid arthritis treated with methotrexate

Modern Rheumatology, 09/13/2011

Watanabe K et al. – The authors report the case of a 57–year–old Japanese woman

with rheumatoid arthritis (RA) who developed de–novo hepatitis B virus–related

hepatitis after methotrexate (MTX) therapy. Entecavir and oral prednisolone

following steroid pulse therapy were administered and her liver function

recovered.

• MTX is widely used for RA for its efficiency and safety.

• But some cases of HBV reactivation caused by MTX, including de–novo hepatitis,

have been reported.

• Considering these conditions, more attention should be paid when using MTX in

patients with RA.

• And more studies are needed to determine who needs screening of HBV,

monitoring of HBV–DNA, and prophylaxis with chemotherapy or immunosuppressive

therapy.

-----------------------------------------------------

http://www.springerlink.com/content/0760265302x23516/

Modern Rheumatology

DOI: 10.1007/s10165-011-0521-9Online First™

Case Report

Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative

patient with rheumatoid arthritis treated with methotrexate

Keisuke Watanabe, Kaoru Takase, Shigeru Ohno, Haruko Ideguchi, Akito Nozaki and

Yoshiaki Ishigatsubo

Abstract

Immunosuppressive therapy can induce viral reactivation in patients with chronic

hepatitis B virus (HBV) infection and, more rarely, in patients with resolved

HBV infection. We report the case of a 57-year-old Japanese woman with

rheumatoid arthritis (RA) who developed de-novo hepatitis B virus-related

hepatitis after methotrexate (MTX) therapy. Entecavir and oral prednisolone

following steroid pulse therapy were administered and her liver function

recovered. MTX is widely used for RA for its efficiency and safety. But some

cases of HBV reactivation caused by MTX, including de-novo hepatitis, have been

reported. Considering these conditions, more attention should be paid when using

MTX in patients with RA. And more studies are needed to determine who needs

screening of HBV, monitoring of HBV-DNA, and prophylaxis with chemotherapy or

immunosuppressive therapy. Abstract

Immunosuppressive therapy can induce viral reactivation in patients with chronic

hepatitis B virus (HBV) infection and, more rarely, in patients with resolved

HBV infection. We report the case of a 57-year-old Japanese woman with

rheumatoid arthritis (RA) who developed de-novo hepatitis B virus-related

hepatitis after methotrexate (MTX) therapy. Entecavir and oral prednisolone

following steroid pulse therapy were administered and her liver function

recovered. MTX is widely used for RA for its efficiency and safety. But some

cases of HBV reactivation caused by MTX, including de-novo hepatitis, have been

reported. Considering these conditions, more attention should be paid when using

MTX in patients with RA. And more studies are needed to determine who needs

screening of HBV, monitoring of HBV-DNA, and prophylaxis with chemotherapy or

immunosuppressive therapy. Abstract

Immunosuppressive therapy can induce viral reactivation in patients with chronic

hepatitis B virus (HBV) infection and, more rarely, in patients with resolved

HBV infection. We report the case of a 57-year-old Japanese woman with

rheumatoid arthritis (RA) who developed de-novo hepatitis B virus-related

hepatitis after methotrexate (MTX) therapy. Entecavir and oral prednisolone

following steroid pulse therapy were administered and her liver function

recovered. MTX is widely used for RA for its efficiency and safety. But some

cases of HBV reactivation caused by MTX, including de-novo hepatitis, have been

reported. Considering these conditions, more attention should be paid when using

MTX in patients with RA. And more studies are needed to determine who needs

screening of HBV, monitoring of HBV-DNA, and prophylaxis with chemotherapy or

immunosuppressive therapy. Abstract

Immunosuppressive therapy can induce viral reactivation in patients with chronic

hepatitis B virus (HBV) infection and, more rarely, in patients with resolved

HBV infection. We report the case of a 57-year-old Japanese woman with

rheumatoid arthritis (RA) who developed de-novo hepatitis B virus-related

hepatitis after methotrexate (MTX) therapy. Entecavir and oral prednisolone

following steroid pulse therapy were administered and her liver function

recovered. MTX is widely used for RA for its efficiency and safety. But some

cases of HBV reactivation caused by MTX, including de-novo hepatitis, have been

reported. Considering these conditions, more attention should be paid when using

MTX in patients with RA. And more studies are needed to determine who needs

screening of HBV, monitoring of HBV-DNA, and prophylaxis with chemotherapy or

immunosuppressive therapy. Abstract

Immunosuppressive therapy can induce viral reactivation in patients with chronic

hepatitis B virus (HBV) infection and, more rarely, in patients with resolved

HBV infection. We report the case of a 57-year-old Japanese woman with

rheumatoid arthritis (RA) who developed de-novo hepatitis B virus-related

hepatitis after methotrexate (MTX) therapy. Entecavir and oral prednisolone

following steroid pulse therapy were administered and her liver function

recovered. MTX is widely used for RA for its efficiency and safety. But some

cases of HBV reactivation caused by MTX, including de-novo hepatitis, have been

reported. Considering these conditions, more attention should be paid when using

MTX in patients with RA. And more studies are needed to determine who needs

screening of HBV, monitoring of HBV-DNA, and prophylaxis with chemotherapy or

immunosuppressive therapy.

[Guest guest]

http://www.mdlinx.com/infectious-disease/newsl-article.cfm/3750503/ZZ68065536792\

5639220014/?news_id=497 & newsdt=091311 & subspec_id=130

Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative

patient with rheumatoid arthritis treated with methotrexate

Modern Rheumatology, 09/13/2011

Watanabe K et al. – The authors report the case of a 57–year–old Japanese woman

with rheumatoid arthritis (RA) who developed de–novo hepatitis B virus–related

hepatitis after methotrexate (MTX) therapy. Entecavir and oral prednisolone

following steroid pulse therapy were administered and her liver function

recovered.

• MTX is widely used for RA for its efficiency and safety.

• But some cases of HBV reactivation caused by MTX, including de–novo hepatitis,

have been reported.

• Considering these conditions, more attention should be paid when using MTX in

patients with RA.

• And more studies are needed to determine who needs screening of HBV,

monitoring of HBV–DNA, and prophylaxis with chemotherapy or immunosuppressive

therapy.

-----------------------------------------------------

http://www.springerlink.com/content/0760265302x23516/

Modern Rheumatology

DOI: 10.1007/s10165-011-0521-9Online First™

Case Report

Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative

patient with rheumatoid arthritis treated with methotrexate

Keisuke Watanabe, Kaoru Takase, Shigeru Ohno, Haruko Ideguchi, Akito Nozaki and

Yoshiaki Ishigatsubo

Abstract

Immunosuppressive therapy can induce viral reactivation in patients with chronic

hepatitis B virus (HBV) infection and, more rarely, in patients with resolved

HBV infection. We report the case of a 57-year-old Japanese woman with

rheumatoid arthritis (RA) who developed de-novo hepatitis B virus-related

hepatitis after methotrexate (MTX) therapy. Entecavir and oral prednisolone

following steroid pulse therapy were administered and her liver function

recovered. MTX is widely used for RA for its efficiency and safety. But some

cases of HBV reactivation caused by MTX, including de-novo hepatitis, have been

reported. Considering these conditions, more attention should be paid when using

MTX in patients with RA. And more studies are needed to determine who needs

screening of HBV, monitoring of HBV-DNA, and prophylaxis with chemotherapy or

immunosuppressive therapy. Abstract

Immunosuppressive therapy can induce viral reactivation in patients with chronic

hepatitis B virus (HBV) infection and, more rarely, in patients with resolved

HBV infection. We report the case of a 57-year-old Japanese woman with

rheumatoid arthritis (RA) who developed de-novo hepatitis B virus-related

hepatitis after methotrexate (MTX) therapy. Entecavir and oral prednisolone

following steroid pulse therapy were administered and her liver function

recovered. MTX is widely used for RA for its efficiency and safety. But some

cases of HBV reactivation caused by MTX, including de-novo hepatitis, have been

reported. Considering these conditions, more attention should be paid when using

MTX in patients with RA. And more studies are needed to determine who needs

screening of HBV, monitoring of HBV-DNA, and prophylaxis with chemotherapy or

immunosuppressive therapy. Abstract

Immunosuppressive therapy can induce viral reactivation in patients with chronic

hepatitis B virus (HBV) infection and, more rarely, in patients with resolved

HBV infection. We report the case of a 57-year-old Japanese woman with

rheumatoid arthritis (RA) who developed de-novo hepatitis B virus-related

hepatitis after methotrexate (MTX) therapy. Entecavir and oral prednisolone

following steroid pulse therapy were administered and her liver function

recovered. MTX is widely used for RA for its efficiency and safety. But some

cases of HBV reactivation caused by MTX, including de-novo hepatitis, have been

reported. Considering these conditions, more attention should be paid when using

MTX in patients with RA. And more studies are needed to determine who needs

screening of HBV, monitoring of HBV-DNA, and prophylaxis with chemotherapy or

immunosuppressive therapy. Abstract

Immunosuppressive therapy can induce viral reactivation in patients with chronic

hepatitis B virus (HBV) infection and, more rarely, in patients with resolved

HBV infection. We report the case of a 57-year-old Japanese woman with

rheumatoid arthritis (RA) who developed de-novo hepatitis B virus-related

hepatitis after methotrexate (MTX) therapy. Entecavir and oral prednisolone

following steroid pulse therapy were administered and her liver function

recovered. MTX is widely used for RA for its efficiency and safety. But some

cases of HBV reactivation caused by MTX, including de-novo hepatitis, have been

reported. Considering these conditions, more attention should be paid when using

MTX in patients with RA. And more studies are needed to determine who needs

screening of HBV, monitoring of HBV-DNA, and prophylaxis with chemotherapy or

immunosuppressive therapy. Abstract

Immunosuppressive therapy can induce viral reactivation in patients with chronic

hepatitis B virus (HBV) infection and, more rarely, in patients with resolved

HBV infection. We report the case of a 57-year-old Japanese woman with

rheumatoid arthritis (RA) who developed de-novo hepatitis B virus-related

hepatitis after methotrexate (MTX) therapy. Entecavir and oral prednisolone

following steroid pulse therapy were administered and her liver function

recovered. MTX is widely used for RA for its efficiency and safety. But some

cases of HBV reactivation caused by MTX, including de-novo hepatitis, have been

reported. Considering these conditions, more attention should be paid when using

MTX in patients with RA. And more studies are needed to determine who needs

screening of HBV, monitoring of HBV-DNA, and prophylaxis with chemotherapy or

immunosuppressive therapy.